What's Next For JNJ Stock? [Forbes]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Forbes
The company posted adjusted earnings of $2.77 per share on revenue of $21.9 billion, exceeding consensus estimates of $2.59 per share and $21.6 billion in revenue. This strong performance was largely driven by increased sales of key drugs including Darzalex, Tremfya, and Erleada, supported by growing market share. However, as expected, Stelara experienced a notable 34% year-over-year sales decline to $1.6 billion, due to biosimilar competition. J&J's adjusted net margins remained just under 31%, consistent with the same quarter last year. If you're seeking upside potential with less volatility than individual stocks, take a look at the High-Quality portfolio which has outperformed the S&P and delivered over 91% returns since inception. What's Next For J&J? Looking forward, the company raised its revenue forecast from the prior range of $89.2 billion to $90.0 billion to a revised range of $91.0 billion to $91.8 billion. Meanwhile, it reaffirmed its adjusted EPS guidance of $10.50
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* [Yahoo! Finance]Yahoo! Finance
- U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*PR Newswire
- These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same? [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (NYSE:JNJ) was given a new $197.00 price target on by analysts at Morgan Stanley.MarketBeat
- Is J&J's 45.8% 2025 Surge Justified by Its Cash Flow and Earnings Outlook? [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website